Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
about
Dalcetrapib: a review of Phase II data.HDL and immunomodulation: an emerging role of HDL against atherosclerosis.Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
P2860
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
@en
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
@nl
type
label
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
@en
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
@nl
prefLabel
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
@en
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
@nl
P2860
P1476
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
@en
P2093
Hisashi Shinkai
P2860
P304
P356
10.1517/13543770903198451
P407
P577
2009-09-01T00:00:00Z